Ibogaine Success Rate: What the Research Actually Shows

Ibogaine Success Rate: What the Clinical Data Actually Shows

The ibogaine success rate question is the one nearly every person calls us about first. Here’s the honest answer: there is no reliable single percentage, because only two small prospective studies exist and neither had a control group. The most concrete figure is that half of the 30 participants in Brown & Alper reported no opioid use in the 30 days before their one-month follow-up. Anyone quoting you a confident success rate is quoting something the literature does not support.

This page walks through the actual studies, honest variables, and what we tell every patient before they make any decision. Call (866) 435-7057 to talk it through with an advisor.

The Headline Numbers — and Why They Need Context

Ranges you see quoted elsewhere are wide for a reason: “success” is not uniformly defined. Some studies measure abstinence (no use at all). Others measure significant reduction in use. Others track quality-of-life scores, cravings, or PTSD symptom scales — and a PTSD scale tells you nothing about whether someone stopped using.

Most ibogaine research is also observational — no placebo group, no randomization, often no long-term follow-up beyond 12 months. This limits the evidence hierarchy compared to what we’d demand for an FDA-approved drug. But what we have is consistent enough to take seriously.

Study-by-Study Breakdown

Mash et al. (2000) — St. Kitts Observational Study: One of the earliest rigorous clinical studies, treating opioid-dependent patients at a facility in St. Kitts where ibogaine was legal. The majority experienced significant reduction in withdrawal symptoms within 24–36 hours. At one-month follow-up, a majority reported no opioid use. Foundational, but short follow-up and modest sample size.

Noller et al. (2018) — New Zealand 12-Month Follow-Up: Followed 14 opioid-dependent patients in prescription-regulated New Zealand at 1, 3, and 12 months. At 12 months, participants showed significant reductions in opioid use and dependence severity. Several maintained full-year abstinence. It is the most informative longitudinal data point available, but the small sample limits extrapolation — and one enrolled participant died during treatment, which any honest reading of this literature has to carry.

Brown & Alper (2017) — 30-Patient Observational Study: Mean opioid withdrawal scores (SOWS) fell from 31.0 to 14.0 roughly three days after a single treatment. At one-month follow-up, 15 of the 30 participants — 50% — reported no opioid use in the previous 30 days. Drug-use scores stayed better than baseline from three to twelve months but never again matched the one-month result. That decay is the honest shape of the data, and it is the clearest argument in the literature for taking aftercare seriously.

Stanford VETS Study (2024) — Nature Medicine: The landmark recent study. 30 Special Operations veterans received ibogaine treatment at a clinic in Mexico. Results at one month were large across every measure the study took: functioning (WHODAS, Cohen’s d=2.20), PTSD (d=2.54), depression (d=2.80) and anxiety (d=2.13), alongside cognitive gains after TBI. Stanford’s own summary puts the average PTSD reduction at about 88%. One thing to be clear about on a page like this: the study measured TBI, PTSD, depression and anxiety — it did not measure alcohol or substance use outcomes, so it is not evidence about addiction success rates. These numbers generated considerable mainstream attention. Note: a special-operations veteran population is not typical, and the 30-person sample size limits generalizability — but the effect sizes were striking.

Ongoing MAPS-Sponsored Trials: Multiple Phase 2 trials are underway as of 2025 with more rigorous controls than prior observational work. Results are expected to clarify dose-response relationships and long-term outcomes. FDA breakthrough therapy designations for ibogaine-related treatments are actively being discussed.

What “Success” Actually Means

In the strictest sense — total abstinence at 12 months — ibogaine success rates probably sit in the 30–50% range. When the definition broadens to significant reduction in use, improved functioning, and return to baseline quality of life, the numbers move closer to 60–80%.

Neither definition is wrong. They measure different things. At Psychedelic Connect, we ask every patient to define what success looks like for them before they walk into any clinic. That conversation shapes everything.

Variables That Affect Outcomes

Addiction type: Ibogaine has the strongest evidence for opioid use disorder. Evidence for stimulant addiction and alcohol is more limited and less consistent.

Integration support: Brown & Alper (2018) identified this as a major predictor. Patients with structured aftercare maintained gains at substantially higher rates than those without. Ibogaine can interrupt the cycle; integration builds something new in its place.

Medical setting: Studies in medically supervised settings with proper screening showed better safety profiles — higher-risk cardiac patients were screened out appropriately, which improves both safety and outcome data.

Treatment history: Patients with shorter addiction histories tend to fare better. But many who reach ibogaine have already exhausted conventional options — the data still supports its use for treatment-resistant cases.

Dose and protocol: Sub-therapeutic doses produce incomplete results. The alkaloid profile, dosing protocol, and medical supervision vary significantly between clinics.

Ibogaine vs. Conventional Detox

Standard opioid detox without MAT has 70–90% relapse rates at 12 months. Medication-assisted treatment with buprenorphine or methadone significantly reduces overdose deaths and improves functional outcomes — but requires ongoing maintenance. Most patients who stop Suboxone or methadone relapse at high rates.

Ibogaine is the only treatment in the evidence base that consistently interrupts acute opioid withdrawal within 24–48 hours while simultaneously addressing underlying neurological patterns. The most effective approach for many patients is ibogaine followed by naltrexone (Vivitrol) as a bridge — combining rather than choosing.

Who Responds Best

Best candidates: Opioid-dependent patients who are medically stable; patients with co-occurring trauma or PTSD; patients who have failed conventional treatment; veterans with TBI/PTSD/SUD (the Stanford data is specifically relevant).

Not appropriate for: Patients with cardiac conditions (especially QT prolongation or arrhythmias), liver disease, active untreated psychosis, or those on certain medications (SSRIs unreduced, QT-prolonging drugs, unreduced opioid agonists). See our Ibogaine Safety Guide for a complete breakdown.

What Happens After Relapse

Relapse after ibogaine happens. When it does, the cause is usually an integration gap (the reset happened but the patient returned to the same environment with no support) or an incomplete initial response (particularly with long-term, high-dose fentanyl dependence). Some clinics offer re-treatment protocols with meaningful recovery rates for patients who relapsed and then engaged seriously with integration.

What Psychedelic Connect Tells Patients

We hold every clinic we recommend to our published standard, before we will send anyone there. We would rather lose a referral than point someone somewhere we have not put through that standard. The patients who do best go in medically prepared, with realistic expectations, and come out with a plan for what happens next.

Call us at (866) 435-7057 or visit our consultation page. Before committing to anything, read our Ibogaine Safety Guide.

Frequently Asked Questions

What is the ibogaine success rate for opioid addiction?
The two published prospective studies are small. Brown & Alper (n=30) found 50% reporting no opioid use in the prior 30 days at one month, with improvement decaying but holding above baseline to twelve months. Noller et al. (n=14) found significant reductions in drug use and dependence severity at twelve months. Treat any single headline percentage with suspicion — these are open-label studies without control groups.

How does ibogaine compare to methadone or Suboxone?
Methadone and Suboxone are maintenance medications requiring ongoing use. Ibogaine interrupts acute withdrawal and addresses neurological patterns in a single treatment. Many patients use ibogaine followed by naltrexone (Vivitrol) as a bridge — combining rather than choosing.

Is one ibogaine treatment enough?
For many patients, one treatment produces a significant interruption of dependence. Outcomes are strongly tied to integration support afterward. Some patients with long-term high-dose fentanyl dependence benefit from a second treatment.

What did the Stanford veterans study find?
In 30 Special Operations veterans with traumatic brain injury, it found large one-month improvements in functioning, PTSD, depression and anxiety, plus cognitive gains. It did not measure substance use, and it had no control group.

Who should not pursue ibogaine?
Patients with cardiac conditions (especially QT prolongation), liver disease, untreated psychosis, or on certain medications. Medical screening is not optional — it’s what separates safe treatment from dangerous one.

How do I find a legitimate ibogaine clinic?
Look for on-site medical staff, cardiac screening protocols (EKG prior to treatment), psychological pre-screening, and structured integration programs. Call (866) 435-7057 — we’ve evaluated clinics against these criteria before making referrals.

Psychedelic Connect is a treatment advisory service. We do not provide medical advice. Ibogaine treatment involves serious medical considerations including cardiac risks. Always consult a qualified medical professional before pursuing any treatment.